![The primary goal of the Paradigm Registry is to accelerate tumor profiling based on disease biology. [iStock/LilliDay]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/307-218x150.jpeg "AI Algorithm Could Reduce Breast Cancer Mammogram False Positive Rate")
GeneDx’ subsidiary BioReference Laboratories published results in Genetics in Medicine from a retrospective review of molecular diagnostic testing by whole exome sequencing (WES). According to GeneDx, it is the largest dataset of its kind published to date and demonstrates that WES is more successful in providing a definitive diagnosis for patients with rare and complex genetic conditions when parents or other affected family members are included in the analysis (trio approach). It also revealed new disease-causing genes.
GeneDx reviewed 3,040 consecutive WES cases over three years to better understand how WES could provide a genetic diagnosis for symptoms in an affected individual. The review showed WES to be a powerful clinical tool for diagnosing genetic conditions, especially in patients with severe or multisystemic conditions.
To read the rest of this article click here.
